Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021

Rhea-AI Summary

Kamada Ltd. (NASDAQ: KMDA) will release its financial results for Q2 2021 on August 11, before U.S. markets open. A conference call to discuss these results will follow at 8:30 AM ET, available via telephone or a live webcast. The company's leading products include GLASSIA® and KEDRRAB®, with GLASSIA being the first FDA-approved liquid AAT product. Kamada is also advancing clinical trials for inhaled AAT and a hyperimmune IgG product for COVID-19. FIMI Opportunity Fund is the lead shareholder, owning approximately 21% of the company.

Positive

• Kamada is advancing two significant clinical trials: inhaled AAT for AAT deficiency and a hyperimmune IgG product for COVID-19.
• The strategic partnership with Takeda allows Kamada to benefit from GLASSIA royalties until 2040.

Negative

• None.

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open of the U.S. financial markets on Wednesday, August 11, 2021.

Kamada management will host an investment community conference call on Wednesday, August 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13721962. The call will also be webcast live on the Internet at http://public.viavid.com/index.php?id=145993.

The call will also be archived for 90 days on the Company’s website at www.kamada.com.

About Kamada
Kamada Ltd. (the “Company”) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company’s two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ("Takeda") and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, and a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will Kamada release its financial results for Q2 2021?

Kamada will release its financial results for the three and six months ended June 30, 2021, on August 11, 2021.

What time is the Kamada conference call to discuss financial results?

The conference call is scheduled for August 11, 2021, at 8:30 AM ET.

What are Kamada's leading products?

Kamada's leading products are GLASSIA® and KEDRRAB®.

Who is the lead shareholder of Kamada?

FIMI Opportunity Fund is the lead shareholder, owning approximately 21% of Kamada.